...
首页> 外文期刊>Diabetes, obesity & metabolism >Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects
【24h】

Glucose-lowering effect of the DPP-4 inhibitor sitagliptin after glucose and non-glucose macronutrient ingestion in non-diabetic subjects

机译:DPP-4抑制剂西他列汀在非糖尿病受试者中摄取葡萄糖和非葡萄糖大量营养素后的降糖作用

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: Recent studies suggest that the incretin concept is not restricted to glucose ingestion but relevant also after non-glucose macronutrient administration. We therefore hypothesized that raising incretin hormones reduces circulating glucose after both glucose and non-glucose macronutrient ingestion in healthy subjects. Methods: Twelve healthy subjects received the dipeptidyl peptidase-4 inhibitor sitagliptin (100mg) or placebo before ingestion of glucose, fat (olive oil) or protein mix in equicaloric amounts (8 kcal/kg) plus paracetamol (1.5g). The 120-min areas under curve (AUC) of intact glucagon-like peptide-1 (GLP-1), glucose, insulin, C-peptide, glucagon and paracetamol, and model-derived insulin secretion rate (ISR), insulin sensitivity, insulin clearance and glucose absorption were measured. Results: The increased plasma intact GLP-1 levels after each macronutrient was augmented by sitagliptin. This was associated with a robust lowering of glucose: glucose excursion after oral glucose was diminished, and glucose fell below baseline after oral fat and protein. In spite of lower glucose, AUCC-peptide and ISR did not differ significantly between sitagliptin and placebo after any macronutrient. AUCglucagon, insulin sensitivity and insulin clearance were also not different between sitagliptin and placebo. Glucose absorption after oral glucose was reduced by sitagliptin, whereas AUCparacetamol was not statistically different between sitagliptin and placebo. Conclusions: Physiological elevation of intact GLP-1 levels after ingestion of glucose and non-glucose macronutrients is robustly glucose-lowering in healthy subjects. Hence, the incretin concept is not restricted to glucose ingestion in normal physiology. The glucose-lowering action of sitagliptin at these low glucose levels in healthy subjects may have complex mechanisms, involving both islet-dependent and islet-independent mechanisms.
机译:目的:最近的研究表明肠降血糖素的概念不仅限于葡萄糖的摄入,而且与非葡萄糖大量营养素给药后有关。因此,我们假设在健康受试者中,摄入肠降血糖素激素后会减少葡萄糖和非葡萄糖大量营养素的摄入,从而降低循环葡萄糖。方法:12名健康受试者接受二肽基肽酶4抑制剂西他列汀(100mg)或安慰剂,然后以等热量(8 kcal / kg)加对乙酰氨基酚(1.5g)摄入葡萄糖,脂肪(橄榄油)或蛋白质混合物。完整的胰高血糖素样肽1(GLP-1),葡萄糖,胰岛素,C肽,胰高血糖素和扑热息痛的曲线下区域(AUC)120分钟,以及模型衍生的胰岛素分泌率(ISR),胰岛素敏感性,测量胰岛素清除率和葡萄糖吸收。结果:西他列汀可增加每种常量营养素后血浆完整GLP-1水平的升高。这与葡萄糖的强烈降低有关:口服葡萄糖减少后葡萄糖偏移减少,口服脂肪和蛋白质后葡萄糖降至基线以下。尽管葡萄糖含量较低,但西他列汀和安慰剂之间的任何常量营养素后,AUCC肽和ISR均无显着差异。西他列汀和安慰剂之间的AUC胰高血糖素,胰岛素敏感性和胰岛素清除率也无差异。西他列汀可降低口服葡萄糖后的葡萄糖吸收,而西他列汀和安慰剂之间的AUC对乙酰氨基酚无统计学差异。结论:摄取葡萄糖和非葡萄糖大量营养素后,完整GLP-1水平的生理升高可在健康受试者中显着降低葡萄糖。因此,肠降血糖素的概念不限于正常生理中的葡萄糖摄取。西他列汀在健康受试者中处于这些低葡萄糖水平时的降糖作用可能具有复杂的机制,涉及胰岛依赖性和胰岛非依赖性机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号